hVIVO Plc.

(Ticker: HVO) is a full-service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world’s ten largest biopharma companies. hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London—the largest of its kind worldwide. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector. The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development. 2 P's on a Pod: Small Cap Investing with Paul Hill & Paul Scott Sep 18, 2026 hVIVO Interim Results: Mo Khan on Guidance, Growth and What Comes Next Sep 15, 2026 hVIVO Expands Specialist Clinical Trial Capabilities with CRS Berlin Sep 1, 2026 2 P's on a Pod: Small Cap Investing with Paul Hill & Paul Scott Aug 28, 2026 2 P’s on a Pod: Small Cap Investing with Paul Hill & Paul Scott Jul 23, 2026 2 P's on a Pod: Is M&A a Key Signal in Equity Markets Right Now? May 15, 2026 hVIVO Secures £6m Influenza Human Challenge Trial Contract May 7, 2026 2 P’s on a Pod: Small Cap Investing with Paul Hill & Paul Scott Apr 24, 2026 hVIVO Lands Landmark Phase III Trial Apr 22, 2026 2 P’s on a Pod: Small Cap Investing with Paul Hill & Paul Scott Apr 15, 2026 Investment & Valuation Crib Sheet Sep 21, 2026 hVIVO - Interim Results Presentation Oct 3, 2025 H1 25 Trading Update Aug 20, 2025